Approval

Israel approves ImmunityBio's ANKTIVA with BCG for BCG-unresponsive bladder cancer

Israel's health ministry cleared ANKTIVA, given together with BCG, for adults whose non-muscle-invasive bladder tumours include carcinoma in situ and no longer respond to BCG. The review took four months, and the formal registration license should follow within weeks. Rafa Laboratories will sell the drug in Israel, and the companies count 35 countries where ANKTIVA is now authorized.

Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call